Evaluation of Salivary Proteomic and Genomic Biomarkers as Non-Invasive Diagnostic Tools for Early Detection of Alzheimer's and Parkinson's Diseases: A Schematic Assessment and Meta-Analysis
DOI:
https://doi.org/10.36283/ziun-pjmd14-3/078Keywords:
Alzheimer's Disease / Diagnosis , Parkinson's Disease / Diagnosis , Biomarkers , Biological / Analysis, , Saliva / Chemistry, ProteomicsAbstract
Background: Salivary biomarkers are non-invasive molecules that indicate neurodegenerative illnesses, especially Alzheimer disease (AD) and Parkinson disease (PD).this study was conducted to determine the diagnostic precision of salivary proteomic and genomic biomarkers in terms of early AD and PD detection.
Methods: A systematic literature search was conducted in PubMed, web of science and Google Scholar, and studies included from 2016 to 2025. Research that examined salivary biomarkers in AD and PD was eligible. The data were analyzed with a random-effects model and odds ratios (OR), standard mean differences (SMD), and 95% confidence interval (CI) was estimated. Also, subgroup and sensitivity analysis were performed. To assess the risk of bias, the Newcastle-Ottawa Scale (NOS) was applied for included observational studies.
Results: A total of 11 eligible studies concerning proteomic biomarkers, including amyloid-β (Aβ42, Aβ40) and alpha-synuclein total (α-synTotal) and alpha-synuclein Oligomer (α-synOligo), and genomic biomarkers like different salivary microRNAs were included. Meta-analysis indicated that Aβ42 (OR=0.70; 95% CI: 0.41 to 1.1) and Aβ40 (OR=1.01; 95% CI: 0.97 to 1.06) had significant discriminatory potential in AD patients; but α-synOligo (SMD = 2.90; 95% CI: -0.59–6.39) and α-synTotal (SMD = 0.44; 95% CI: -3.14 to 4.02) was higher in PD patients as compared with controls. Genomic biomarkers demonstrated inconsistent findings (SMD = -0.18; 95% CI: -1.79–1.42) because of difference in microRNA types. Heterogeneity was high (I2 > 90%), which is caused by alterations in study design and in the methods to measure biomarkers.
Discussion: Salivary biomarkers were found to be an insignificant yet exceptional method of early examination of AD and PD. Nonetheless, the inconsistency of different studies points to develop standardized protocols.
References
1. Culberson JW, Kopel J, Sehar U, Reddy PH. Urgent needs of caregiving in ageing populations with Alzheimer’s disease and other chronic conditions: Support our loved ones. Ageing Res Rev. 2023 Sep;90:102001. doi:10.1016/j.arr.2023.102001.
2. Perl DP, Olanow CW, Calne D. Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol. 1998 Sep;44(3 Suppl 1):S19-31. doi:10.1002/ana.410440705.
3. Caligiore D, Giocondo F, Silvetti M. The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. IBRO Neurosci Rep. 2022 Dec;13:330–343. doi:10.1016/j.ibneur.2022.09.007.
4. Song M, Bai H, Zhang P, Zhou X, Ying B. Promising applications of human-derived saliva biomarker testing in clinical diagnostics. Int J Oral Sci. 2023 Jan;15(1):1–17. doi:10.1038/s41368-022-00209-w.
5. Goldoni R, Dolci C, Boccalari E, Inchingolo F, Paghi A, Strambini L, et al. Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection. Ageing Res Rev. 2022 Apr;76:101587. doi:10.1016/j.arr.2022.101587.
6. Dongiovanni P, Meroni M, Casati S, Goldoni R, Thomaz DV, Kehr NS, et al. Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation. Int J Oral Sci. 2023 Jun;15:27. doi:10.1038/s41368-023-00231-6.
7. Koh DSQ, Koh GCH. The use of salivary biomarkers in occupational and environmental medicine. Occup Environ Med. 2007 Mar;64(3):202. doi:10.1136/oem.2006.026567.
8. Constantin V, Luchian I, Goriuc A, Budala DG, Bida FC, Cojocaru C, et al. Salivary Biomarkers Identification: Advances in Standard and Emerging Technologies. Oral. 2025 Jun;5(2):26. doi:10.3390/oral5020026.
9. Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson’s disease: A state of the art review. Biomarkers Neuropsychiatry. 2023 Dec;9:100074. doi:10.1016/j.bionps.2023.100074.
10. Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023 Oct;15:175. doi:10.1186/s13195-023-01314-6.
11. Andersen E, Casteigne B, Chapman WD, Creed A, Foster F, Lapins A, et al. Diagnostic biomarkers in Alzheimer’s disease. Biomarkers Neuropsychiatry. 2021 Dec;5:100041. doi:10.1016/j.bionps.2021.100041.
12. Contini C, Fadda L, Lai G, Masala C, Olianas A, Castagnola M, et al. A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson’s disease with respect to Alzheimer’s disease patients and to healthy controls. Proteomics. 2024 Feb;24(3-4):e2300202. doi:10.1002/pmic.202300202.
13. Contini C, Serrao S, Manconi B, Olianas A, Iavarone F, Guadalupi G, et al. Characterization of Cystatin B Interactome in Saliva from Healthy Elderly and Alzheimer’s Disease Patients. Life (Basel). 2023 Mar;13(3):748. doi:10.3390/life13030748.
14. Contini C, Serrao S, Manconi B, Olianas A, Iavarone F, Bizzarro A, et al. Salivary Proteomics Reveals Significant Changes in Relation to Alzheimer’s Disease and Aging. J Alzheimers Dis. 2022;89(2):605–622. doi:10.3233/JAD-220246.
15. Chen X, Huang Y, Bao T, Jia F, Ou R, Wei Q, et al. Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer’s Disease Patients. Front Aging Neurosci. 2021;13:790939. doi:10.3389/fnagi.2021.790939.
16. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, et al. Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer’s Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci. 2017;9:26. doi:10.3389/fnagi.2017.00026.
17. McNicholas K, François M, Liu JW, Doecke JD, Hecker J, Faunt J, et al. Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer’s disease in a feasibility study. Front Aging Neurosci. 2022;14:1019296. doi:10.3389/fnagi.2022.1019296.
18. Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR, et al. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer’s disease. Neuroimage Clin. 2014;4:461–472. doi:10.1016/j.nicl.2013.12.012.
19. Sabaei M, Rahimian S, Haj Mohamad Ebrahim Ketabforoush A, Rasoolijazi H, Zamani B, Hajiakhoundi F, et al. Salivary levels of disease-related biomarkers in the early stages of Parkinson’s and Alzheimer’s disease: A cross-sectional study. IBRO Neurosci Rep. 2023 Jun;14:285–292. doi:10.1016/j.ibneur.2023.03.004.
20. Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease. Parkinsonism Relat Disord. 2015 Jul;21(7):758–764. doi:10.1016/j.parkreldis.2015.04.027.
21. Rani K, Rastogi S, Vishwakarma P, Bharti PS, Sharma V, Renu K, et al. A novel approach to correlate the salivary exosomes and their protein cargo in the progression of cognitive impairment into Alzheimer’s disease. J Neurosci Methods. 2021 Jan;347:108980. doi:10.1016/j.jneumeth.2020.108980.
22. Yerramalla MS, Darin-Mattsson A, Udeh-Momoh CT, Holleman J, Kåreholt I, Aspö M, et al. Cognitive reserve, cortisol, and Alzheimer’s disease biomarkers: A memory clinic study. Alzheimers Dement. 2024 Jul;20(7):4486–4498. doi:10.1002/alz.13866.
23. Eldem E, Barve A, Sallin O, Foucras S, Annoni JM, Schmid AW, et al. Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion. J Alzheimers Dis Rep. 2022;6(1):31–41. doi:10.3233/ADR-210056.
24. Xu Y, Ding Y, Li X, Wu X. Cystatin C is a disease‐associated protein subject to multiple regulation. Immunol Cell Biol. 2015;93(5):442–451. doi:10.1038/icb.2014.121.
25. Sheikh AM, Wada Y, Tabassum S, Inagaki S, Mitaki S, Yano S, et al. Aggregation of Cystatin C Changes Its Inhibitory Functions on Protease Activities and Amyloid β Fibril Formation. Int J Mol Sci. 2021 Jan;22(18):9682. doi:10.3390/ijms22189682.
26. Koníčková D, Menšíková K, Tučková L, Hényková E, Strnad M, Friedecký D, et al. Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status. Biomedicines. 2022 Jul;10(7):1760. doi:10.3390/biomedicines10071760.
27. Wei R, Zhang Y, Li P, Aisha A, Nuerlanbieke H, Niyazi A, et al. Value of blood biomarkers in the diagnosis of Parkinson’s disease: a case-control study from Xinjiang. BMC Neurol. 2025 Mar;25:118. doi:10.1186/s12883-025-04121-8.
28. Picillo M, Moccia M, Spina E, Barone P, Pellecchia MT. Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. JPRLS. 2016 Feb;6:1–13. doi:10.2147/JPRLS.S85488.
29. Chen X, Huang Y, Bao T, Jia F, Ou R, Wei Q, et al. Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer’s Disease Patients. Front Aging Neurosci. 2022 Jan;13:790939. doi:10.3389/fnagi.2021.790939.
30. Lu Y, Dong W, Xue X, Sun J, Yan J, Wei X, et al. The severity assessment of Parkinson’s disease based on plasma inflammatory factors and third ventricle width by transcranial sonography. CNS Neurosci Ther. 2024 Mar;30(3):e14670. doi:10.1111/cns.14670.
31. Zhang C, Ma J, Gao H, Luo Y, Feng J, Wei Y, et al. Investigation of serum cystatin C levels and their diagnostic value in combination with inflammatory ratios in patients with bipolar disorder. Front Psychiatry. 2025 Apr;16:1525091. doi:10.3389/fpsyt.2025.1525091.
32. Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010 Dec;14(6):584–588. doi:10.1007/s10157-010-0334-8.
33. Levy E. Cystatin C in Alzheimer’s disease. Front Mol Neurosci. 2012 Jul;5. doi:10.3389/fnmol.2012.00079.
34. Mathews PM, Levy E. Cystatin C in aging and in Alzheimer’s disease. Ageing Res Rev. 2016 Dec;32:38–50. doi:10.1016/j.arr.2016.06.003.
35. Xiong KP, Dai YP, Chen J, Xu JM, Wang Y, Feng P, et al. Increased Serum Cystatin C in Early Parkinson’s Disease with Objective Sleep Disturbances. Chin Med J. 2018 Apr;131(8):907. doi:10.4103/0366-6999.229902.
36. J S, J S, O H, M EJ, V G, A L, et al. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer’s disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis. 2010;21(2). doi:10.3233/JAD-2010-091594.
37. Ruan Q, D’Onofrio G, Sancarlo D, Greco A, Yu Z. Potential fluid biomarkers for pathological brain changes in Alzheimer’s disease: Implication for the screening of cognitive frailty. Mol Med Rep. 2016 Oct;14(4):3184–3198. doi:10.3892/mmr.2016.5618.
38. Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed). 2011 Jan;3:541–554. doi:10.2741/s170.
39. Hällqvist J, Bartl M, Dakna M, Schade S, Garagnani P, Bacalini MG, et al. Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset. Nat Commun. 2024 Jun;15(1):4759. doi:10.1038/s41467-024-48961-3.
40. Dong Y, Song X, Wang X, Wang S, He Z. The early diagnosis of Alzheimer’s disease: Blood-based panel biomarker discovery by proteomics and metabolomics. CNS Neurosci Ther. 2024;30(11):e70060. doi:10.1111/cns.70060.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
